Clinical Trial Update: A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. [Phase 1, Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 1/2 clinical trial evaluating the feasibility of combining three agents (Quizartinib, Plerixafor, Ganetespib) with c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• High-risk Myelodysplastic Syndrome

Drugs mentioned

• Ganetespib (ganetespib)
• Plerixafor (Plerixafor)
• Quizartinib (Quizartinib)

Snippet

Sponsor: Cardiff University | Conditions: Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome | Phase 1, Phase 2 | Status: COMPLETED